Clinical trial Recruiting at 1 site Interventional Ages 18 to 100

Using FTIRS to detect and limit spread of ESBL-producing bacteria in ICUs

Official title: Impact of Fourier Transform Infrared Spectroscopy (FTIRS) on the Diffusion of ESBL Producing Enterobacterales in Intensive Care Units (ICU)

Run by University Hospital, Caen · NCT05872152 · Data updated 2026-11-12

We will test whether a rapid FTIRS bacterial typing test for adult ICU patients who carry ESBL-producing Enterobacterales can reduce spread between patients.

Quick facts

Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment900 (estimated)
SponsorUniversity Hospital, Caen
Academic / other
Locations1 site (Caen)
StatusRecruiting
StartedJanuary 8, 2024
Main results expectedSeptember 1, 2026
Study endsSeptember 1, 2026
Registry record updatedJuly 24, 2025
Trial IDNCT05872152 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults admitted to the participating ICU who are carriers of ESBL-producing Enterobacterales (identified by rectal swab) are the intended participants.

Probably not a fit

Patients who are not colonized with ESBL-producing bacteria or who are treated outside the participating ICU are unlikely to receive direct benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Multidrug-resistant Enterobacterales, particularly ESBL-producing strains, pose a high risk of cross-transmission in intensive care units. This interventional study implements routine FTIRS typing of ESBL-E from rectal swabs to deliver rapid (about one hour) strain identification that can inform infection-control measures. FTIRS results will be used alongside standard culture workflows, recognizing whole genome sequencing (WGS/MLST/SNP) as the gold standard but less feasible for continuous surveillance. The study will compare cross-transmission rates before and after systematic FTIRS implementation to determine its impact on ESBL-E spread in the ICU.

Why it matters

Potential benefit: If successful, routine FTIRS typing could reduce ICU spread of ESBL-producing bacteria and lower related infections and transmission events.

How similar studies have gone: FTIRS has shown promising rapid-typing accuracy in validation studies, but there is limited evidence from large clinical trials demonstrating reduced transmission compared with current practice or sequencing.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients hospitalized in ICU
* ESBL-E carrier

Exclusion Criteria:

* none

Where it's running

  • Chu Chen
    Caen, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.